Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Medical Ethics|April 19, 2022
Patient portal access for caregivers of adult and geriatric patients: reframing the ethics of digital patient communicationTeja Ganta, Jacob M Appel, Nicholas Genes
Cancer Letters|March 18, 2014
Is reduction of tumor burden sufficient for the 21st century?George Nahas, Sarah A Bliss, Garima Sinha, et al.
The Annals of Thoracic Surgery|September 16, 2018
Tumor Lysis Syndrome After Bilobectomy for Typical Carcinoid Tumor of the LungThomas H Shin, Elica Inagaki, Teja Ganta, et al.
JAMA Network Open|July 10, 2024
Fairness in Predicting Cancer Mortality Across Racial SubgroupsTeja Ganta, Arash Kia, Prathamesh Parchure, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 17, 2015
The RNA-binding protein Musashi 1 stabilizes the oncotachykinin 1 mRNA in breast cancer cells to promote cell growthGeorge R Nahas, Raghav G Murthy, Shyam A Patel, et al.
Clinical Genitourinary Cancer|October 22, 2024
The Association of Statin Use With Survival Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Androgen Receptor Targeted Therapies (ART)Zakaria Chakrani, Mann Patel, George Mellgard, et al.
International Journal of Molecular Sciences|October 14, 2023
Clinical Significance of Extracellular Vesicles in Prostate and Renal CancerTzu-Yi Chen, Meredith Mihalopoulos, Laura Zuluaga, et al.
Clinical Lung Cancer|February 28, 2025
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) PatientsAdriana P C Barrichello, Arielle Elkrief, Biagio Ricciuti, et al.
Cancer Letters|June 5, 2024
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort studyKylie Fletcher, Alessio Cortellini, Teja Ganta, et al.
JAMA Oncology|November 4, 2021
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort StudyCaroline A Nebhan, Alessio Cortellini, Weijie Ma, et al.
Pageof 1